SolAeroMed is the leader in biophysical
respiratory drugs.

Learn More


Cystic Fibrosis, Bronchiectasis, Asthma Rescue Drug & other chronic obstructive lung diseases including COVID-19
In Phase II Clinical Trials


Surfactant Dysfunction
In Pre-Clinical Development



About SolAeroMed

SolAeroMed is a company dedicated to the development of novel therapeutic strategies to treat obstructive lung diseases. Our lead drug, S-1226, is in Phase II clinical trials designed to demonstrate Proof of Concept.

SolAeroMed is seeking development partners for our platform technology respiratory products.

Learn More